Overbought Stocks
RVMD appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
REVOLUTION MEDICINES INC (RVMD) Stock Price & Overview
NASDAQ:RVMD • US76155X1000
Current stock price
136.3 USD
+39.87 (+41.35%)
At close:
134 USD
-2.3 (-1.69%)
Pre-Market:
The current stock price of RVMD is 136.3 USD. Today RVMD is up by 41.35%. In the past month the price increased by 43.69%. In the past year, price increased by 270.78%.
RVMD Key Statistics
52-Week Range34 - 136.8
Current RVMD stock price positioned within its 52-week range.
1-Month Range91.52 - 136.8
Current RVMD stock price positioned within its 1-month range.
- Market Cap
- 27.011B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.91
- Dividend Yield
- N/A
RVMD Stock Performance
Today
+41.35%
1 Week
+42.93%
1 Month
+43.69%
3 Months
+13.32%
Longer-term
6 Months +151.94%
1 Year +270.78%
2 Years +265.61%
3 Years +480.25%
5 Years +310.67%
10 Years N/A
RVMD Stock Chart
RVMD Stock Screens
RVMD currently appears in the following ChartMill screener lists.
RSI Overbought Stocks
RVMD is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
Breakout Stocks
RVMD is part of our breakout stocks list, indicating it is showing strong recent technical strength.
RVMD Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RVMD. When comparing the yearly performance of all stocks, RVMD is one of the better performing stocks in the market, outperforming 97.52% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RVMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RVMD. While RVMD seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RVMD Earnings
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$1.86
Revenue Reported
EPS Surprise -15.36%
Revenue Surprise -100.00%
RVMD Forecast & Estimates
27 analysts have analysed RVMD and the average price target is 136.84 USD. This implies a price increase of 0.4% is expected in the next year compared to the current price of 136.3.
For the next year, analysts expect an EPS growth of -33.36% and a revenue growth 1132.72% for RVMD
Analysts
Analysts87.41
Price Target136.84 (0.4%)
EPS Next Y-33.36%
Revenue Next Year1132.72%
RVMD Groups
Sector & Classification
RVMD Financial Highlights
Over the last trailing twelve months RVMD reported a non-GAAP Earnings per Share(EPS) of -5.91. The EPS decreased by -65.55% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.13B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.05% | ||
| ROE | -69.35% | ||
| Debt/Equity | 0.16 |
Chartmill High Growth Momentum
EPS Q2Q%-66.07%
Sales Q2Q%N/A
EPS 1Y (TTM)-65.55%
Revenue 1Y (TTM)N/A
RVMD Ownership
Ownership
Inst Owners100.23%
Shares198.17M
Float190.64M
Ins Owners1.92%
Short Float %7.58%
Short Ratio5.75
RVMD Latest News, Press Relases and Analysis
RVMD Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 365.196B | ||
| AMGN | AMGEN INC | 15.32 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| BIIB | BIOGEN INC | 10.94 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.34 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RVMD
Company Profile
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Company Info
IPO: 2020-02-13
REVOLUTION MEDICINES INC
700 Saginaw Dr
Redwood City CALIFORNIA 94063 US
CEO: Mark A. Goldsmith
Employees: 883
Phone: 13026365400
REVOLUTION MEDICINES INC / RVMD FAQ
What does REVOLUTION MEDICINES INC do?
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. The company is headquartered in Redwood City, California and currently employs 883 full-time employees. The company went IPO on 2020-02-13. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
What is the current price of RVMD stock?
The current stock price of RVMD is 136.3 USD. The price increased by 41.35% in the last trading session.
What is the dividend status of REVOLUTION MEDICINES INC?
RVMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVMD stock?
RVMD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of RVMD stock?
REVOLUTION MEDICINES INC (RVMD) operates in the Health Care sector and the Biotechnology industry.
Who owns REVOLUTION MEDICINES INC?
You can find the ownership structure of REVOLUTION MEDICINES INC (RVMD) on the Ownership tab.